Given our observations both in vivo and in vitro that Stx2 leads to a reduction in GEnC CFH binding and subsequent endothelial complement activation, we attempted to rescue the HUS phenotype using the C5 complement inhibitor BB5.1. This evidence concerns the gene STX2 and hemolytic-uremic syndrome.